electroCore to present at European headache meeting on non-invasive vagus nerve stimulation therapy for cluster headache

18 September 2014

This weekend, at the European Headache and Migraine Trust International Congress in Copenhagen (EHMTIC), electroCore will be presenting full data on their PREVA study, a randomized, multi-centre trial across several European countries.

The trial showed that preventative use of non-invasive vagus nerve stimulation (nVNS) can substantially reduce the frequency of cluster headache attacks (ie by 43.4%) versus the control group (the current standard of care, which experienced only a 12% reduction).

Three poster presentations will provide full details of the PREVA trial and include:

  • A report on the randomized phase
  • A report on the open label phase
  • An analysis of quality of life impact

On Saturday evening electroCore is hosting a satellite symposium with three eminent headache specialists:

  • Professor Jean Schoen, Director of the Headache Research Unit at the University of Liège, Belgium, who will provide an overview of Neuromodulation and the role of non-invasive vagus nerve (nVNS) stimulation.
  • Dr Charly Gaul, Director of the Migraine and Headache Clinic Königstein, Germany and the principle investigator of the PREVA trial who will comprehensively explore the use of nVNS in the prevention of cluster headache.
  • Professor Stephen Silberstein, Director of the Thomas Jefferson Headache Centre at the Thomas Jefferson University and Hospitals Philadelphia, who will present data on nVNS in the prevention of chronic migraine.

New Jersey based electroCore has developed non-invasive Vagus Nerve Stimulation (nVNS) therapies, which are self-administered by patients for the treatment of multiple conditions in neurology, psychiatry, respiratory and other fields.


To top